All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
6 warning events since 2019; the latest 2026-03-20.
From the record
Valion Bio, Inc.'s filings since 2019 show 6 warning events: a notice about its exchange listing (8-K item 3.01, 6 times, the latest 2026-03-20) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-14.7% a year over 4 filed years; profitable in 0 of 4.
From the record
Valion Bio, Inc.'s 4 filed years say what it did: revenue went from $1 million in fiscal 2021 to $780 thousand in fiscal 2024, down 14.7% a year; it rose in 1 of 3 years; the deepest fall was 58% from fiscal 2022 to fiscal 2024; net income was positive in 0 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 0.6/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Valion Bio, Inc.'s shareholder treatment is put at 0.6 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 6% of 27 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -53%: lost 53¢ per shareholder dollar. Leverage 47%: owes 47¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Valion Bio, Inc. lost about 53 cents for every dollar of shareholders' money. Leverage: it owed about 47 cents per dollar of assets, and net share issuance: its share count grew 302.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 12% of 24 in its family; net margin -725%.
From the record
Valion Bio, Inc.'s standing among 24 graded names in its industry family: revenue of $780 thousand in fiscal 2024 ranks in the bottom 15% by size; a net margin of -725% ranks in the bottom 15%; revenue growth of -14.7% a year over the last 3 filed years ranks in the bottom 6% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 9% of 19 in its family for leadership; chief executive since 2026.
From the record
Valion Bio, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Zikria, Dean (Interim CEO, as filed), filing under that title since 2026-09-24, 2 months (bottom 3% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 2.1 years (bottom 15%); 15 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (bottom 10%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
SI estimate 8.3/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Valion Bio, Inc.'s room to expand is put at 8.3 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 17% of 27 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
bottom 50% of 25 in its family for growth drivers.
From the record
Valion Bio, Inc.'s growth drivers, from the filed years to fiscal 2024: revenue grew -14.7% a year over the last three filed years against -14.7% over all 4, speeding up (top 46% of its family); the newest year grew -33.6% (bottom 2%); research spending grew 21.9% a year (top 30%); capital spending grew 51.2% a year (top 27%) (its annual reports). Valion Bio, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 30% of 20 in its family for expectations against reality.
From the record
Valion Bio, Inc.'s newest year against its own record: revenue of $780 thousand in fiscal 2024 came in 31.4% below the $1 million its prior three years' pace pointed to (bottom 7% of its family); net income of $6 million against a prior three-year average of $9 million (top 25%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 8%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made